Continuous Glucose Monitoring of Steroid-Induced Hyperglycemia in Patients With Dermatologic Diseases
Authors' conclusion
Our study underlines the need for dedicated glucose monitoring in dermatologic patients on systemic glucocorticoid therapy by demonstrating its impact on glucose metabolism.
Study context
- Population
- Steroid-naive dermatological inpatients requiring systemic high-dose glucocorticoid treatment, Department of Dermatology, University Hospital Essen
- Participants
- 51 inpatients
- Exposure
- Normoglycemia vs Prediabetes vs Diabetes
- Normoglycemian = 10
- Prediabetesn = 10
- Diabetesn = 10
- Outcome
- Incidence and severity of steroid-induced hyperglycemia (SIH) by CGM
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
SIH incidence
Normoglycemia
2
events
Prediabetes
4
events
Diabetes
9
events
- SIH in all treated patients
- 47.1%
Observational data: associations, not effects.
Further findings
Glucose profile in patients with SIH (continuous glucose monitoring (CGM))
- Time above targeted glucose range
- nearly 6 hours daily
- Severe hyperglycemia
- 1.2 hours/day
Original publication
Continuous Glucose Monitoring of Steroid-Induced Hyperglycemia in Patients With Dermatologic Diseases. J Diabetes Sci Technol. Published 5 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →